Evaluation of Protein in the Urine in Patients Receiving Bevacizumab
Evaluation of Protein in the Urine in Patients Receiving Bevacizumab
This is a clinical research study to look at the incidence of proteinuria (a condition in
 which urine contains an abnormal amount of protein) caused by shortened infusions (given into
 the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or
 breast cancer). There are currently no published studies or clinical data looking at how safe
 shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We
 hypothesis that shortened infusions of bevacizumab will result in an increased risk for
 proteinuria compared to the standard infusions of this agent.
Inclusion Criteria:

 -  Patients must be 18 years older

 -  Patients must be receiving his/her first dose of bevacizumab

 -  Patients must sign an informed consent

 Exclusion Criteria:

 -  Patients receiving > 10 mg/kg doses of bevacizumab